{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Evolus, Inc."},"Symbol":{"label":"Symbol","value":"EOLS"},"Address":{"label":"Address","value":"520 NEWPORT CENTER DRIVE,SUITE 1200, NEWPORT BEACH, California, 92660, United States"},"Phone":{"label":"Phone","value":"+1 949 284-4555"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary of 900 kilodalton or kDa, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the self-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications that are not reimbursed by any third-party payor, such as Medicaid, Medicare or commercial insurance."},"CompanyUrl":{"label":"Company Url","value":"https://www.evolus.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"David Moatazedi","title":"President, Chief Executive Officer & Director"},{"name":"Rui Avelar","title":"Chief Medical Officer, Head-Research & Development"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}